Paul D A, Knigge M F, Ritter A, Gutierrez R, Pilot-Matias T, Chau K H, Dawson G J
Abbott Laboratories, North Chicago, IL 60064.
J Infect Dis. 1994 Apr;169(4):801-6. doi: 10.1093/infdis/169.4.801.
Recombinant antigens from hepatitis E virus (HEV) open-reading frames 2 and 3 were expressed in Escherichia coli as cytidine monophosphate-2-keto-3-deoxyoctulosonic acid synthetase (CKS) fusion proteins, purified, and used to develop an EIA for the detection of antibodies. Serologic results were compared with those of previous assays by testing 102 samples from an HEV outbreak in Somalia. This CKS/HEV EIA detected anti-HEV in all 97 sera found reactive previously and in an additional 2 samples, which were shown to be true HEV-positive samples by supplemental peptide and Western blot tests. The CKS/HEV EIA and supplemental assays were then used to determine seroprevalence of HEV worldwide. HEV seroprevalence ranged from 1% to 25%, with higher rates found in Middle Eastern countries. Also, 7%-14% of acute cases of non-A, -B, or -C hepatitis were HEV-positive. Thus, this CKS/HEV EIA appears useful for detecting anti-HEV in various populations.
戊型肝炎病毒（HEV）开放阅读框2和3的重组抗原在大肠杆菌中作为胞苷单磷酸-2-酮-3-脱氧辛糖酸合成酶（CKS）融合蛋白表达，经纯化后用于开发一种检测抗体的酶免疫分析（EIA）。通过检测来自索马里一次戊型肝炎病毒暴发的102份样本，将血清学检测结果与之前检测方法的结果进行比较。这种CKS/HEV EIA在之前检测为反应性的所有97份血清以及另外2份样本中检测到了抗HEV，经补充肽和蛋白质印迹试验证实这2份样本为真正的戊型肝炎病毒阳性样本。随后，利用CKS/HEV EIA和补充检测方法来确定全球戊型肝炎病毒的血清流行率。戊型肝炎病毒血清流行率在1%至25%之间，中东国家的流行率较高。此外，7%至14%的非甲、非乙、非丙型肝炎急性病例为戊型肝炎病毒阳性。因此，这种CKS/HEV EIA似乎可用于检测不同人群中的抗HEV。
